Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma

David T. Marshall, Stephen J Ramey, Ali Reza Golshayan, Thomas E. Keane, Andrew S. Kraft, Uzair Chaudhary

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background This was a phase I study to find the maximum tolerable dose (MTD) of weekly docetaxel combined with high-dose intensity-modulated radiotherapy (IMRT) and androgen deprivation therapy (ADT). Patients and Methods Men with localized high-risk prostate cancer (HRPC) were treated with weekly docetaxel at 10 to 30 mg/m2 concurrent with IMRT of 77.4 Gy to the prostate and 45 Gy to the seminal vesicles. ADT consisted of a gonadotropin-releasing hormone agonist (GnRHa) and bicalutamide beginning 2 months before and during chemoradiation. GnRHa was continued for 24 months. Results Nineteen patients were enrolled. No dose-limiting toxicity (DLT) was seen with docetaxel doses up to 25 mg/m2. At the 30 mg/m2 level, 2 of 4 patients experienced DLTs of both grade 3 fatigue and dyspepsia. At 41 months' median follow-up, 2 patients had died - 1 from metastatic prostate cancer and the other from heart failure. Two other patients experienced biochemical failure. One patient with bladder invasion at diagnosis experienced late grade 2 urinary hesitancy 9 months after completion of radiotherapy, requiring short-term intermittent catheterization. All patients had erectile dysfunction, but no late toxicities worse than grade 2 were identified. Conclusion Weekly docetaxel may be combined with high-dose IMRT and long-term ADT up to a MTD of 25 mg/m2. Acute toxicities and long-term side effects of this regimen were acceptable. Future studies evaluating the efficacy of docetaxel, ADT, and IMRT for localized HRPC should use a weekly dose of 25 mg/m2 when limiting the irradiated volume to the prostate and seminal vesicles.

Original languageEnglish (US)
Pages (from-to)80-86
Number of pages7
JournalClinical Genitourinary Cancer
Volume12
Issue number2
DOIs
StatePublished - Apr 2014
Externally publishedYes

Fingerprint

docetaxel
Image-Guided Radiotherapy
Intensity-Modulated Radiotherapy
Androgens
Prostate
Adenocarcinoma
Prostatic Neoplasms
Seminal Vesicles
Gonadotropin-Releasing Hormone
Dyspepsia
Delayed Diagnosis
Erectile Dysfunction
Therapeutics
Catheterization
Fatigue
Urinary Bladder
Radiotherapy
Heart Failure

Keywords

  • Androgen deprivation therapy
  • Docetaxel
  • High-risk prostate cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. / Marshall, David T.; Ramey, Stephen J; Golshayan, Ali Reza; Keane, Thomas E.; Kraft, Andrew S.; Chaudhary, Uzair.

In: Clinical Genitourinary Cancer, Vol. 12, No. 2, 04.2014, p. 80-86.

Research output: Contribution to journalArticle

Marshall, David T. ; Ramey, Stephen J ; Golshayan, Ali Reza ; Keane, Thomas E. ; Kraft, Andrew S. ; Chaudhary, Uzair. / Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. In: Clinical Genitourinary Cancer. 2014 ; Vol. 12, No. 2. pp. 80-86.
@article{f35dcc9a006d4563b0473df88261ddd5,
title = "Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma",
abstract = "Background This was a phase I study to find the maximum tolerable dose (MTD) of weekly docetaxel combined with high-dose intensity-modulated radiotherapy (IMRT) and androgen deprivation therapy (ADT). Patients and Methods Men with localized high-risk prostate cancer (HRPC) were treated with weekly docetaxel at 10 to 30 mg/m2 concurrent with IMRT of 77.4 Gy to the prostate and 45 Gy to the seminal vesicles. ADT consisted of a gonadotropin-releasing hormone agonist (GnRHa) and bicalutamide beginning 2 months before and during chemoradiation. GnRHa was continued for 24 months. Results Nineteen patients were enrolled. No dose-limiting toxicity (DLT) was seen with docetaxel doses up to 25 mg/m2. At the 30 mg/m2 level, 2 of 4 patients experienced DLTs of both grade 3 fatigue and dyspepsia. At 41 months' median follow-up, 2 patients had died - 1 from metastatic prostate cancer and the other from heart failure. Two other patients experienced biochemical failure. One patient with bladder invasion at diagnosis experienced late grade 2 urinary hesitancy 9 months after completion of radiotherapy, requiring short-term intermittent catheterization. All patients had erectile dysfunction, but no late toxicities worse than grade 2 were identified. Conclusion Weekly docetaxel may be combined with high-dose IMRT and long-term ADT up to a MTD of 25 mg/m2. Acute toxicities and long-term side effects of this regimen were acceptable. Future studies evaluating the efficacy of docetaxel, ADT, and IMRT for localized HRPC should use a weekly dose of 25 mg/m2 when limiting the irradiated volume to the prostate and seminal vesicles.",
keywords = "Androgen deprivation therapy, Docetaxel, High-risk prostate cancer, Radiotherapy",
author = "Marshall, {David T.} and Ramey, {Stephen J} and Golshayan, {Ali Reza} and Keane, {Thomas E.} and Kraft, {Andrew S.} and Uzair Chaudhary",
year = "2014",
month = "4",
doi = "10.1016/j.clgc.2013.11.019",
language = "English (US)",
volume = "12",
pages = "80--86",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma

AU - Marshall, David T.

AU - Ramey, Stephen J

AU - Golshayan, Ali Reza

AU - Keane, Thomas E.

AU - Kraft, Andrew S.

AU - Chaudhary, Uzair

PY - 2014/4

Y1 - 2014/4

N2 - Background This was a phase I study to find the maximum tolerable dose (MTD) of weekly docetaxel combined with high-dose intensity-modulated radiotherapy (IMRT) and androgen deprivation therapy (ADT). Patients and Methods Men with localized high-risk prostate cancer (HRPC) were treated with weekly docetaxel at 10 to 30 mg/m2 concurrent with IMRT of 77.4 Gy to the prostate and 45 Gy to the seminal vesicles. ADT consisted of a gonadotropin-releasing hormone agonist (GnRHa) and bicalutamide beginning 2 months before and during chemoradiation. GnRHa was continued for 24 months. Results Nineteen patients were enrolled. No dose-limiting toxicity (DLT) was seen with docetaxel doses up to 25 mg/m2. At the 30 mg/m2 level, 2 of 4 patients experienced DLTs of both grade 3 fatigue and dyspepsia. At 41 months' median follow-up, 2 patients had died - 1 from metastatic prostate cancer and the other from heart failure. Two other patients experienced biochemical failure. One patient with bladder invasion at diagnosis experienced late grade 2 urinary hesitancy 9 months after completion of radiotherapy, requiring short-term intermittent catheterization. All patients had erectile dysfunction, but no late toxicities worse than grade 2 were identified. Conclusion Weekly docetaxel may be combined with high-dose IMRT and long-term ADT up to a MTD of 25 mg/m2. Acute toxicities and long-term side effects of this regimen were acceptable. Future studies evaluating the efficacy of docetaxel, ADT, and IMRT for localized HRPC should use a weekly dose of 25 mg/m2 when limiting the irradiated volume to the prostate and seminal vesicles.

AB - Background This was a phase I study to find the maximum tolerable dose (MTD) of weekly docetaxel combined with high-dose intensity-modulated radiotherapy (IMRT) and androgen deprivation therapy (ADT). Patients and Methods Men with localized high-risk prostate cancer (HRPC) were treated with weekly docetaxel at 10 to 30 mg/m2 concurrent with IMRT of 77.4 Gy to the prostate and 45 Gy to the seminal vesicles. ADT consisted of a gonadotropin-releasing hormone agonist (GnRHa) and bicalutamide beginning 2 months before and during chemoradiation. GnRHa was continued for 24 months. Results Nineteen patients were enrolled. No dose-limiting toxicity (DLT) was seen with docetaxel doses up to 25 mg/m2. At the 30 mg/m2 level, 2 of 4 patients experienced DLTs of both grade 3 fatigue and dyspepsia. At 41 months' median follow-up, 2 patients had died - 1 from metastatic prostate cancer and the other from heart failure. Two other patients experienced biochemical failure. One patient with bladder invasion at diagnosis experienced late grade 2 urinary hesitancy 9 months after completion of radiotherapy, requiring short-term intermittent catheterization. All patients had erectile dysfunction, but no late toxicities worse than grade 2 were identified. Conclusion Weekly docetaxel may be combined with high-dose IMRT and long-term ADT up to a MTD of 25 mg/m2. Acute toxicities and long-term side effects of this regimen were acceptable. Future studies evaluating the efficacy of docetaxel, ADT, and IMRT for localized HRPC should use a weekly dose of 25 mg/m2 when limiting the irradiated volume to the prostate and seminal vesicles.

KW - Androgen deprivation therapy

KW - Docetaxel

KW - High-risk prostate cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84896394942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896394942&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2013.11.019

DO - 10.1016/j.clgc.2013.11.019

M3 - Article

C2 - 24378335

AN - SCOPUS:84896394942

VL - 12

SP - 80

EP - 86

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 2

ER -